Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

clostridium difficile

- PMLiVE

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada

- PMLiVE

eureKARE to use $60m financing to bolster next-generation European biotech companies

New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology

- PMLiVE

Seres’ microbiome-based therapy hits the mark in phase 3

Drug reduced C.difficile infection recurrence

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

Finch’s microbiota drug for C. diff gets FDA breakthrough status

Boost for firm as it races rivals in microbiome space

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

All the latest from the frontlines of healthcare

- PMLiVE

Roche digs out soil drug discovery deal with Lodo

Lodo is raiding the rich microbial world of soil for potential new drugs

- PMLiVE

Microbiome specialist Rebiotix chalks up C. diff trial success

Drug therapy can prevent recurrent infections

- PMLiVE

After delay, Merck gets US approval for serious infection drug

Zinplava anticipated to accrue $300m in sales by 2020

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Sanofi vaccine against GI ‘superbug’ starts phase III

Aims to protect against Clostridium difficile

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links